Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 26 September 2024, Online, European Medicines Agency, Amsterdam, the Netherlands, from 26 September 2024, 10:00 (CEST) to 26 September 2024, 13:00 (CEST)

Superseded community herbal monograph on Rosmarinus officinalis L., folium

List of centrally authorised products with safety-related changes to the product information

Human medicines European public assessment report (EPAR): Giapreza, angiotensin II, Date of authorisation: 23/08/2019, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): Tuznue, trastuzumab, Date of authorisation: 19/09/2024, Status: Authorised

Human medicines European public assessment report (EPAR): Tuznue, trastuzumab, Date of authorisation: 19/09/2024, Status: Authorised

Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Hemgenix, etranacogene dezaparvovec, Date of authorisation: 20/02/2023, Revision: 4, Status: Authorised

List of eligible industry stakeholder organisations

Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 1, Status: Authorised